NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

NewAmsterdam Pharma (Nasdaq: NAMS) announced inducement equity grants to two non-executive new hires under its 2024 Inducement Plan on March 2, 2026. The Compensation Committee approved options for 10,000 ordinary shares at an exercise price of $32.83 and 2,200 restricted stock units.

Options vest over four years (25% after one year, then monthly over 36 months). RSUs vest over three years in equal one-third annual installments. Awards are subject to plan and award agreement terms and Nasdaq Listing Rule 5635(c)(4).

NAARDEN, the Netherlands and MIAMI, March 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 10,000 of NewAmsterdam’s ordinary shares to two non-executive new hires. The share options were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).

The share options have an exercise price per share equal to $32.83, which represents the closing market price on the Nasdaq Stock Market of the Company’s ordinary shares on March 2, 2026, the grant date. The shares subject to the options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 equal monthly installments thereafter, subject to each employee’s continued service with NewAmsterdam on such vesting dates. The options are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of an option award agreement covering the grant.

The Compensation Committee of NewAmsterdam’s Board of Directors also approved the grant of restricted stock units covering an aggregate of 2,200 of NewAmsterdam’s ordinary shares to two non-executive new hires. The restricted stock units were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the 2024 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units were granted on March 2, 2026. The restricted stock units will vest over three years, with one-third of the restricted stock units vesting on each of the one-year, two-year and three-year anniversaries of the applicable vesting commencement date, subject to each employee’s continued service with NewAmsterdam on such vesting dates. The restricted stock units are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of a restricted stock unit award agreement covering the grant.

About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com

FAQ

What inducement grants did NewAmsterdam (NAMS) approve on March 2, 2026?

NewAmsterdam approved options for 10,000 shares and 2,200 restricted stock units. According to NewAmsterdam, the awards were granted as inducements under the 2024 Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4).

What is the exercise price and grant date for the NAMS share options?

The options were granted on March 2, 2026 with an exercise price of $32.83. According to NewAmsterdam, that price equals the Nasdaq closing market price on the grant date.

How do the NAMS option vesting terms work for the new hires?

The options vest over four years: 25% after one year, then monthly over 36 months. According to NewAmsterdam, vesting is subject to each employee's continued service on applicable vesting dates.

What are the vesting terms for the 2,200 RSUs granted by NewAmsterdam (NAMS)?

The RSUs vest over three years with one-third vesting each year on the first, second and third anniversaries. According to NewAmsterdam, vesting is conditioned on continued service and the award agreement terms.

Were the inducement grants to NAMS executives or non-executive new hires?

The awards were granted to two non-executive new hires as inducements to join the company. According to NewAmsterdam, the Compensation Committee approved the grants under the 2024 Inducement Plan and Nasdaq rules.